GO:0016874 ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016874 ligase activity is a molecular function defined as the catalysis of joining two molecules or two groups within a single molecule using energy from ATP, a similar triphosphate, or a pH gradient [QuickGO].
• Ligases include E3 ubiquitin ligases such as Parkin (PRKN), which are activated by PINK1-mediated phosphorylation of ubiquitin and play key roles in mitophagy and inflammation [1,2].
• Dysregulated ligase activity contributes to cancer, neurodegeneration, and immune disorders; for example, HERC3 promotes YAP/TAZ stability independently of its ubiquitin ligase activity in tumorigenesis.
• Small molecules and molecular glues can modulate ligase activity, offering therapeutic strategies for Parkinson's disease and cancer [3,7].
• Engineered peptide ligases, such as those derived from bamboo asparaginyl endopeptidase, expand the toolbox for bioconjugation and protein engineering.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential for dissecting the causal roles of ligases in disease and validating drug targets.
Description
Ligase activity (GO:0016874) is a fundamental molecular function that enables the joining of two molecules or two groups within a single molecule, driven by the hydrolysis of ATP, a similar triphosphate, or a pH gradient [QuickGO]. This activity is essential for numerous biological processes, including DNA repair, protein ubiquitination, and peptide bond formation. Researchers study ligases to understand how cells maintain genomic integrity, regulate protein turnover, and respond to stress. The importance of ligase activity is underscored by its involvement in human diseases such as Parkinson's disease, cancer, and inflammatory disorders [1,2,5]. For instance, the E3 ubiquitin ligase Parkin (PRKN) is activated by PINK1-mediated phosphorylation of ubiquitin, a key step in mitophagy and neuroprotection. Moreover, Parkin and PINK1 mitigate STING-induced inflammation, linking ligase dysfunction to innate immune responses. These findings highlight ligases as critical nodes in cellular signaling and as promising therapeutic targets. Understanding the molecular mechanisms, regulation, and disease relevance of ligase activity is therefore a major focus of biomedical research.
ligase activity At A Glance
| GO ID | GO:0016874 |
|---|---|
| GO term | ligase activity |
| Ontology | molecular_function |
| Synonym | synthetase activity |
| Definition | Catalysis of the joining of two molecules, or two groups within a single molecule, using the energy from the hydrolysis of ATP, a similar triphosphate, or a pH gradient. |
| Major function | Formation of covalent bonds between molecules or within a molecule, often coupled to ATP hydrolysis. |
| Examples | E3 ubiquitin ligases (e.g., Parkin, HERC3), peptide ligases, SUMO E3 ligase SIZ1. |
| Related diseases | Parkinson's disease, cancer, inflammatory disorders. |
What Is GO:0016874?
According to the Gene Ontology, ligase activity (GO:0016874) is defined as the catalysis of the joining of two molecules, or two groups within a single molecule, using the energy from the hydrolysis of ATP, a similar triphosphate, or a pH gradient. This definition encompasses enzymes that form covalent bonds between substrates, often coupled to the cleavage of high-energy phosphate bonds. Ligases are distinct from other enzymes because they consume energy to drive bond formation, which is essential for biosynthetic pathways and molecular repair. The term is synonymous with synthetase activity, reflecting the synthetic nature of the reaction. Ligases are classified under the molecular_function aspect of the Gene Ontology and are involved in diverse processes such as DNA ligation, ubiquitination, and amino acid activation.
Why Is ligase activity Important in Cell Biology?
Ligase activity is central to countless cellular processes, from DNA replication and repair to protein degradation and immune signaling. The ability to join molecules with high specificity and energy coupling makes ligases indispensable for maintaining cellular homeostasis. Dysregulation of ligase activity is linked to severe human diseases, including neurodegeneration, cancer, and autoimmunity [1,2,5]. For example, loss of Parkin ligase activity leads to impaired mitophagy and increased inflammation, contributing to Parkinson's disease [1,2]. In cancer, HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity, revealing non-canonical roles. Moreover, ligases are attractive drug targets, as evidenced by the development of molecular glues that activate Parkin. Understanding ligase mechanisms and regulation is therefore crucial for both basic biology and therapeutic development.
• Ligases are essential for DNA repair, protein ubiquitination, and peptide bond formation.
• Mutations in ligase genes cause neurodegenerative diseases such as Parkinson's disease [1,2].
• Ligase activity regulates immune responses, including STING-induced inflammation.
• Oncogenic ligases like HERC3 promote tumorigenesis through YAP/TAZ stabilization.
• Engineered ligases enable bioconjugation and protein engineering.
• Small-molecule activators of Parkin offer therapeutic potential for Parkinson's disease [3,7].
• SUMO E3 ligases regulate nuclear condensate-mediated immune activation in plants.
• TRIM2 acts as a double-edged sword in apoptosis regulation.
• Ligase activity is critical for protein quality control and cellular stress responses.
• CRISPR screens can identify novel ligase dependencies in cancer and other diseases.
Molecular Mechanism of ligase activity
Substrate recognition and binding
In simple terms: Ligases first grab their target molecules.
Ligases recognize specific substrates through dedicated domains, such as RING or HECT domains in E3 ubiquitin ligases. For example, Parkin binds to phosphorylated ubiquitin and undergoes conformational changes that enable substrate ubiquitination [1,3]. The specificity of substrate recognition ensures that ligases modify only the correct targets, which is critical for cellular signaling. Structural studies have revealed that molecular glues can stabilize active conformations of Parkin, enhancing its ligase activity.
Activation by post-translational modifications
In simple terms: Ligases often need a chemical tag to become active.
Many ligases require post-translational modifications for activation. PINK1 phosphorylates ubiquitin at Ser65, which then binds to Parkin and triggers its E3 ligase activity. This phosphorylation event is a key step in mitophagy. Similarly, SUMO E3 ligase SIZ1 promotes nuclear condensate-mediated immune activation in Arabidopsis, highlighting the role of SUMOylation in plant immunity. These modifications serve as molecular switches that control ligase function in response to cellular signals.
Catalysis and energy coupling
In simple terms: The ligase uses energy to glue molecules together.
Ligases catalyze bond formation by coupling it to the hydrolysis of ATP or a similar triphosphate. For instance, peptide ligases engineered from bamboo asparaginyl endopeptidase efficiently ligate peptides, demonstrating the power of directed evolution to create new ligases. The energy from ATP hydrolysis drives the reaction forward, ensuring that the joining of molecules is thermodynamically favorable. This mechanism is conserved across diverse ligase families, from ubiquitin ligases to DNA ligases.
Regulation by derepression and turnover
In simple terms: Ligases can be turned on by removing inhibitory interactions.
Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase, suggesting that relief of autoinhibition is a key regulatory mechanism. This process involves conformational changes that expose the catalytic site, allowing substrate access. Additionally, ligases themselves can be ubiquitinated and degraded, providing a feedback loop to control their abundance. Such regulatory mechanisms ensure that ligase activity is tightly controlled in space and time.
Non-catalytic functions of ligases
In simple terms: Some ligases have jobs beyond gluing molecules.
Emerging evidence shows that ligases can have non-catalytic functions. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity, indicating that scaffold functions can be decoupled from catalytic activity. This finding expands the functional repertoire of ligases and suggests that targeting their non-catalytic interactions may have therapeutic benefits. Understanding these dual roles is essential for interpreting experimental results and designing drugs.
Key Genes Involved in GO:0016874 ligase activity
The following genes encode proteins with ligase activity or are directly involved in ligase-mediated processes, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKN | E3 ubiquitin ligase; mediates mitophagy and neuroprotection | Parkinson's disease; activated by PINK1 phosphorylation [1,2,3,7] |
| PINK1 | Phosphorylates ubiquitin to activate Parkin | Parkinson's disease; mitophagy regulation [1,2] |
| HERC3 | Promotes YAP/TAZ stability independently of ligase activity | Tumorigenesis; cancer biology |
| TRIM2 | E3 ubiquitin ligase; regulates apoptosis | Neurodegeneration; apoptosis |
| SIZ1 | SUMO E3 ligase; promotes nuclear condensate-mediated immune activation | Plant immunity; SUMOylation |
| UBB | Ubiquitin precursor; substrate for ligases | Protein degradation; stress responses |
| UBA1 | Ubiquitin-activating enzyme; initiates ubiquitination | Global ubiquitination; cell cycle |
| UBE2D1 | Ubiquitin-conjugating enzyme; collaborates with E3 ligases | Protein turnover; DNA repair |
| STING1 | Adaptor in innate immune signaling; regulated by Parkin/PINK1 | Inflammation; autoimmunity |
| YAP1 | Transcriptional co-activator; stabilized by HERC3 | Cancer; organ size control |
| TAZ | Transcriptional co-activator; stabilized by HERC3 | Cancer; differentiation |
| AEP | Asparaginyl endopeptidase; engineered into peptide ligase | Bioconjugation; protein engineering |
| SUMO1 | Small ubiquitin-like modifier; conjugated by SIZ1 | Nuclear condensates; immune signaling |
| CASP3 | Executioner caspase; regulated by TRIM2 | Apoptosis; neurodegeneration |
| MAP1LC3B | Autophagy marker; downstream of Parkin-mediated mitophagy | Autophagy; neurodegeneration [1,7] |
| SQSTM1 | Autophagy receptor; interacts with ubiquitinated substrates | Mitophagy; protein aggregation [1,2] |
| NFE2L2 | Transcription factor; regulated by ubiquitin ligases | Oxidative stress; cancer |
| MDM2 | E3 ubiquitin ligase; targets p53 for degradation | Cancer; cell cycle |
How Is ligase activity Regulated?
Ligase activity is regulated at multiple levels, including post-translational modifications, allosteric regulation, and protein-protein interactions. PINK1-mediated phosphorylation of ubiquitin is a prerequisite for Parkin activation, illustrating a phospho-switch mechanism. Structural derepression of PRKN by endogenous factors leads to increased turnover of the E3 ligase, providing a feedback loop. Molecular glues can stabilize active conformations of Parkin, offering a means to pharmacologically enhance ligase activity. In plants, SUMO E3 ligase SIZ1 promotes nuclear condensate-mediated immune activation, showing that ligase regulation extends to phase separation. Additionally, HERC3 functions independently of its catalytic activity, indicating that non-catalytic regulation can dominate in certain contexts. These diverse mechanisms ensure precise control of ligase function in response to cellular cues.
ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKN | Parkinson's disease; mitophagy | Knockout neurons; point mutation (e.g., T240R); overexpression |
| PINK1 | Parkinson's disease; mitochondrial quality control | Knockout mice; knock-in of phospho-mimetic ubiquitin |
| HERC3 | Cancer; YAP/TAZ stabilization | Knockout cancer cell lines; overexpression of ligase-dead mutant |
| TRIM2 | Neurodegeneration; apoptosis | Knockout mice; point mutation in RING domain |
| SIZ1 | Plant immunity; SUMOylation | Knockout Arabidopsis; overexpression of SUMO1 |
Parkinson's disease and neurodegeneration
Mutations in PRKN and PINK1 are linked to early-onset Parkinson's disease. PINK1 phosphorylates ubiquitin to activate Parkin, initiating mitophagy and protecting neurons from stress. Loss of this pathway leads to accumulation of damaged mitochondria and increased inflammation via STING, contributing to neurodegeneration. Activation of endogenous PRKN by structural derepression increases its turnover, which may be protective or detrimental depending on context. Molecular glues that activate Parkin are being explored as therapeutic strategies.
Cancer and tumorigenesis
HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity, highlighting non-canonical roles of ligases in cancer. This suggests that targeting HERC3's scaffold function, rather than its catalytic activity, may be therapeutically beneficial. Other ligases, such as MDM2, regulate p53 stability and are well-known oncogenes. Dysregulated ligase activity can therefore drive uncontrolled cell proliferation and survival.
Inflammatory and immune disorders
Parkin and PINK1 mitigate STING-induced inflammation, linking mitophagy defects to innate immune activation. This connection implicates ligase dysfunction in autoimmune and inflammatory diseases. Additionally, SUMO E3 ligase SIZ1 promotes nuclear condensate-mediated immune activation in Arabidopsis, demonstrating a conserved role for ligases in immunity. TRIM2, an E3 ubiquitin ligase, acts as a double-edged sword in apoptosis, with implications for immune cell survival.
From ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PRKN impair mitophagy? | PRKN knockout cell lines and neurons |
| Does PINK1 phosphorylation of ubiquitin activate Parkin? | Point mutation of ubiquitin at Ser65 (S65A) knock-in |
| Can molecular glues activate Parkin? | Knock-in of tagged PRKN; overexpression of Parkin with molecular glue treatment |
| Does HERC3 promote tumorigenesis independently of ligase activity? | Knockout of HERC3; overexpression of ligase-dead HERC3 mutant |
| Does TRIM2 regulate apoptosis? | TRIM2 knockout mice; point mutation in RING domain |
| Does SIZ1 mediate immune activation via SUMOylation? | SIZ1 knockout Arabidopsis; overexpression of SIZ1 |
How to Study the ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro ubiquitination assay | Ligase catalytic activity | Testing Parkin activation by PINK1 |
| Mass spectrometry | Ubiquitinated substrates and chain linkages | Identifying HERC3 targets |
| Fluorescence microscopy | Mitophagy flux and protein localization | Visualizing Parkin-mediated mitophagy [1,7] |
| Western blot | Protein stability and ubiquitination | Assessing YAP/TAZ stabilization by HERC3 |
| CRISPR knockout screen | Gene dependencies and modifiers | Discovering regulators of ligase activity |
| RNA-seq | Transcriptional changes | Measuring immune activation by SIZ1 |
| Proximity ligation assay | Protein-protein interactions | Detecting Parkin-ubiquitin binding |
| Surface plasmon resonance | Binding affinity | Characterizing molecular glue-Parkin interactions |
Biochemical assays for ligase activity
In vitro ubiquitination assays using recombinant E1, E2, and E3 enzymes can measure ligase activity by detecting ubiquitin chain formation via Western blot or fluorescence. For Parkin, phosphorylation by PINK1 is required for activation, so assays often include PINK1 and ubiquitin. Peptide ligases can be assayed using fluorescent peptide substrates to monitor ligation efficiency. These methods provide direct readouts of catalytic activity and are essential for validating inhibitors or activators.
Proteomics and ubiquitin chain profiling
Mass spectrometry-based proteomics can identify ubiquitinated substrates and map ubiquitin chain linkages. This approach has been used to study Parkin substrates and the effects of PINK1 phosphorylation. Quantitative proteomics can also reveal changes in protein stability upon ligase manipulation, as shown for HERC3 and YAP/TAZ. These techniques are powerful for unbiased discovery of ligase targets and pathways.
Imaging and cellular assays
Fluorescence microscopy can visualize mitophagy flux using mito-Keima or LC3 reporters in cells with Parkin/PINK1 mutations [1,7]. Immunofluorescence can detect ubiquitin aggregates or STING activation. Live-cell imaging of nuclear condensates can reveal SIZ1-mediated SUMOylation dynamics. These assays link ligase activity to cellular phenotypes and are critical for understanding disease mechanisms.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate ligase activity or sensitivity to ligase inhibitors. For example, screens for Parkin activators or HERC3 dependencies can uncover novel regulators [3,5]. These functional genomics approaches are complemented by transcriptomics and proteomics to build comprehensive networks.
How CRISPR Can Be Used to Study GO:0016874 ligase activity
Knockout
CRISPR knockout of ligase genes such as PRKN, PINK1, or HERC3 enables loss-of-function studies to assess their roles in mitophagy, inflammation, and tumorigenesis [1,2,5]. Knockout cell lines and animal models are essential for validating drug targets and understanding disease mechanisms. For example, PRKN knockout neurons show impaired mitophagy and increased STING signaling.
Point Mutation
Point mutations can be introduced to dissect catalytic versus non-catalytic functions. For instance, mutating the catalytic cysteine in Parkin or HERC3 abolishes ligase activity, allowing researchers to test whether phenotypes depend on catalysis. Phospho-mimetic or phospho-dead mutations in ubiquitin (e.g., S65A) can reveal the importance of PINK1-mediated phosphorylation.
Knock-in
Knock-in of tagged ligases (e.g., HA-PRKN) or disease-associated mutations (e.g., PRKN T240R) allows for precise tracking of protein localization and function. Knock-in of phospho-mutant ubiquitin can elucidate signaling pathways. These models are invaluable for studying endogenous regulation and for drug discovery.
Overexpression
Overexpression of wild-type or mutant ligases can reveal gain-of-function phenotypes and drive disease models. For example, overexpression of HERC3 promotes YAP/TAZ stability and tumorigenesis, while overexpression of ligase-dead HERC3 fails to do so, demonstrating the importance of non-catalytic functions. Overexpression of engineered peptide ligases can enhance bioconjugation efficiency.
How EDITGENE Supports ligase activity Research
Researchers studying ligase activity-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. This requires precise genetic models that can isolate catalytic and non-catalytic functions, mimic disease mutations, and track endogenous protein dynamics. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such investigations.
Contact EDITGENE today to design your custom CRISPR model for ligase activity research.
Frequently Asked Questions About ligase activity
What is ligase activity?
Ligase activity (GO:0016874) is the catalysis of joining two molecules or two groups within a single molecule using energy from ATP hydrolysis or a similar triphosphate, as defined by the Gene Ontology.
What genes are involved in ligase activity?
Key genes include PRKN, PINK1, HERC3, TRIM2, and SIZ1, which encode E3 ubiquitin ligases or related enzymes [1,2,4,5,8].
How is ligase activity regulated?
Ligase activity is regulated by post-translational modifications such as phosphorylation, structural derepression, and protein turnover [1,3,7].
What diseases are associated with ligase dysfunction?
Ligase dysfunction is linked to Parkinson's disease, cancer, and inflammatory disorders [1,2,5].
What is the role of Parkin ligase in Parkinson's disease?
Parkin (PRKN) is activated by PINK1-mediated ubiquitin phosphorylation and mediates mitophagy; loss of function leads to neurodegeneration [1,2].
Can ligase activity be targeted therapeutically?
Yes, molecular glues that activate Parkin and inhibitors of oncogenic ligases are being developed [3,5].
What methods are used to study ligase activity?
Common methods include in vitro ubiquitination assays, mass spectrometry, fluorescence microscopy, and CRISPR screens [1,5,6].
What is the difference between ligase and synthetase?
Ligase activity is synonymous with synthetase activity; both refer to enzymes that join molecules using ATP or similar energy sources.
How do CRISPR models help study ligase function?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of ligase roles in cells and animals [1,5].
What is the role of HERC3 in cancer?
HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Conclusion
Ligase activity (GO:0016874) is a cornerstone of cellular biochemistry, driving essential processes from protein degradation to immune signaling. The diverse roles of ligases in health and disease, exemplified by Parkin, PINK1, HERC3, and TRIM2, underscore their importance as research targets and therapeutic opportunities [1,2,4,5]. Advances in CRISPR genome editing and biochemical assays continue to unravel the complexities of ligase regulation and function. EDITGENE's comprehensive services empower researchers to generate precise models and accelerate discoveries in ligase biology.
References
- 1. Kane LA et al.. 2014. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity.. J Cell Biol 205(2):143-53 PMID: 24751536
- 2. Sliter DA et al.. 2018. Parkin and PINK1 mitigate STING-induced inflammation.. Nature 561(7722):258-262 PMID: 30135585
- 3. Sauvé V et al.. 2024. Activation of parkin by a molecular glue.. Nat Commun 15(1):7707 PMID: 39300082
- 4. Hollemann T. 2025. TRIM2: a double-edged sword preventing apoptosis.. FEBS J 292(2):272-274 PMID: 39617989
- 5. Yuan B et al.. 2023. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.. EMBO J 42(4):e111549 PMID: 36598329
- 6. Wang XB et al.. 2024. An efficient peptide ligase engineered from a bamboo asparaginyl endopeptidase.. FEBS J 291(13):2918-2936 PMID: 38525648
- 7. Fiesel FC et al.. 2025. Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase.. Autophagy 21(12):2750-2770 PMID: 40624741
- 8. Jia M et al.. 2026. SUMO E3 ligase SIZ1 promotes nuclear condensate-mediated immune activation in Arabidopsis.. Nat Commun 17(1) PMID: 41986387
